Aidea Pharma(SH:688488)2025-02-27 10:40Financial Performance - Total revenue for 2024 reached RMB 419.27 million, a year-on-year increase of 1.92%[4] - Operating profit was RMB -151.83 million, a decrease of 64.94% compared to the previous year[6] - Net profit attributable to shareholders of the parent company was RMB -129.92 million, a decline of 70.79% year-on-year[6] - Basic earnings per share were RMB -0.31, compared to RMB -0.18 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 1,909.91 million, an increase of 9.35% from the beginning of the period[6] - Shareholders' equity attributable to the parent company decreased by 11.94% to RMB 991.19 million[6] Expenses - The increase in sales expenses was approximately RMB 21 million due to intensified new drug promotion efforts[6] - Research and development expenses increased by approximately RMB 28 million compared to the previous year[6] - Asset impairment provisions increased by approximately RMB 41.5 million due to changes in market expansion expectations[6] Financial Data Disclaimer - The company emphasizes the preliminary nature of the financial data, which is subject to final confirmation in the annual report[9]